Abstract
Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Current Signal Transduction Therapy
Title: Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Volume: 1 Issue: 2
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, TRAIL, IAP
Abstract: Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012075
DOI https://dx.doi.org/10.2174/157436206777012075 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Considerations for the Management of Turcot’s Syndrome?
Current Cancer Therapy Reviews Preparation and <I>In Vitro/Vivo</I> Evaluation of Folate-conjugated Pluronic F87-PLGA/TPGS Mixed Nanoparticles for Targeted Drug Delivery
Current Drug Delivery Fluorescence Imaging of Human Cells with a Novel Conjugate of the Antifungal Nystatin
Medicinal Chemistry Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
Recent Patents on Anti-Cancer Drug Discovery Translational Multimodality Neuroimaging
Current Drug Targets Adaptor Protein 3BP2 and Cherubism
Current Medicinal Chemistry Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as Co-Ligands
Current Radiopharmaceuticals